secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-021214
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q3 revenue $14.9M; core biopharma up 73% YoY; FY2022 guidance issued
-------------------------------------------------------------------------------

- Q3 2022 revenue $14.9M vs $22.3M in Q3 2021; biopharma ex-VA revenue $14.9M (+73% YoY).
- Net loss $26.5M ($0.58 EPS) vs net loss in prior year; cash $192.8M as of Sept 30, 2022.
- FY2022 guidance: total revenue $63-64M, biopharma ex-VA $55.5-56.5M, net loss $111-114M.
- Won exclusive 5-year VA MVP contract (subject to bidder protest); initial order received.
- Appointed Christopher Hall as SVP, Diagnostic Business; launched NeXT Dx marketing and research collaborations with BC Cancer and Duke.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/psnl-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer